Contact
searchSearch
HMP Global
Login

Myelodysplastic Syndrome Specialty Channel

Myelodysplastic Syndrome
Specialty Channel
FDA Approval
FDA Approves Treosulfan With Fludarabine for Patients With AML or MDS Prior to AlloHSCT
02/07/2025
Emily Estrada
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA...
02/07/2025
Oncology
Benjamin Rolles, MD
Conference Coverage
Impact of Treatment Response to Hypomethylating Agents and Time-to-Transplant Status on Outcomes Among Patients With MDS
01/13/2025
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more...
01/13/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
News
Luspatercept as Novel Standard of Care for ESA-Naive Patients With Transfusion-Dependent, Lower-Risk MDS
10/02/2024
Amber Denham
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new...
10/02/2024
Oncology
News
Initial Low Dose Lenalidomide Over 2 Years Improves Treatment Response Among Non-Transfusion-Dependent Patients With Low-Risk MDS
09/19/2024
Amber Denham
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low...
09/19/2024
Oncology
News
FDA Grants Approval to Imetelstat for Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome With Transfusion-Dependent Anemia
06/21/2024
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to...
06/21/2024
Oncology
Quiz
Safety of Oral Decitabine Cedazuridine vs Intravenous Decitabine for Patients With MDS or CML
06/02/2024
06/02/2024
Oncology
News
Azacitidine Maintenance Demonstrates Lower Disease Progression Rate Among Patients With High-Risk FLT3-Negative AML/MDS
03/05/2024

Amber Denham

Amber Denham
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective...
03/05/2024
Oncology
News
Oral Decitabine Cedazuridine Safe, Effective Alternative to Intravenous Decitabine for Patients With MDS or CML
02/21/2024
Amber Denham
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine...
02/21/2024
Oncology
News
Assessment of Individualized MRD With NGS, ddPCR Effective for Early Detection of MDS Relapse
02/09/2024
Amber Denham
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized...
02/09/2024
Oncology
News
Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes
01/31/2024
Amber Denham
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low...
01/31/2024
Oncology

News

FDA Approval
FDA Approves Treosulfan With Fludarabine for Patients With AML or MDS Prior to AlloHSCT
02/07/2025
Emily Estrada
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA...
02/07/2025
Oncology
Benjamin Rolles, MD
Conference Coverage
Impact of Treatment Response to Hypomethylating Agents and Time-to-Transplant Status on Outcomes Among Patients With MDS
01/13/2025
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more...
01/13/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
News
Luspatercept as Novel Standard of Care for ESA-Naive Patients With Transfusion-Dependent, Lower-Risk MDS
10/02/2024
Amber Denham
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new...
10/02/2024
Oncology
News
Initial Low Dose Lenalidomide Over 2 Years Improves Treatment Response Among Non-Transfusion-Dependent Patients With Low-Risk MDS
09/19/2024
Amber Denham
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low...
09/19/2024
Oncology
News
FDA Grants Approval to Imetelstat for Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome With Transfusion-Dependent Anemia
06/21/2024
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to...
06/21/2024
Oncology
News
Azacitidine Maintenance Demonstrates Lower Disease Progression Rate Among Patients With High-Risk FLT3-Negative AML/MDS
03/05/2024

Amber Denham

Amber Denham
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective...
03/05/2024
Oncology
News
Oral Decitabine Cedazuridine Safe, Effective Alternative to Intravenous Decitabine for Patients With MDS or CML
02/21/2024
Amber Denham
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine...
02/21/2024
Oncology
News
Assessment of Individualized MRD With NGS, ddPCR Effective for Early Detection of MDS Relapse
02/09/2024
Amber Denham
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized...
02/09/2024
Oncology
News
Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes
01/31/2024
Amber Denham
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low...
01/31/2024
Oncology
Luciano Costa, MD
Conference Coverage
Teclistamab Plus Daratumumab Demonstrates Significant Survival Benefit for R/R Multiple Myeloma: MajesTEC-3 Trial
01/30/2026
Luciano J. Costa
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported...
01/30/2026
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
Stephen Lam Chan, MD
Conference Coverage
Adjuvant Pembrolizumab Fails to Improve Recurrence-Free Survival in Hepatocellular Carcinoma
01/26/2026
Stephen Lam Chan, MD
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial which demonstrated that adjuvant pembrolizumab did not significantly improve recurrence-free survival following curative-intent resection or local ablation for...
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial which demonstrated that adjuvant pembrolizumab did not significantly improve recurrence-free survival following curative-intent resection or local ablation for...
Stephen Lam Chan, MD, discusses...
01/26/2026
Oncology

Interactive Features

Quiz
Safety of Oral Decitabine Cedazuridine vs Intravenous Decitabine for Patients With MDS or CML
06/02/2024
06/02/2024
Oncology
Quiz
Eltrombopag for Low-Risk Myelodysplastic Syndromes and Severe Thrombocytopenia
01/05/2024
True or False: Results from the phase 2 EQOL-MDS trial indicated that patients who received eltrombopag demonstrated a higher platelet response and less frequent significant bleeding compared to patients who received a placebo.
True or False: Results from the phase 2 EQOL-MDS trial indicated that patients who received eltrombopag demonstrated a higher platelet response and less frequent significant bleeding compared to patients who received a placebo.
True or False: Results from the...
01/05/2024
Oncology
Quiz
Haploidentical Donors vs Matched Unrelated Donors for High-Risk MDS
06/09/2023
True or False: In a retrospective multicenter study on the use of haploidentical donors for treatment of high-risk MDS, results indicated that overall survival and progression-free survival were significantly higher among patients who...
True or False: In a retrospective multicenter study on the use of haploidentical donors for treatment of high-risk MDS, results indicated that overall survival and progression-free survival were significantly higher among patients who...
True or False: In a...
06/09/2023
Oncology
Quiz
Quiz: Post-Transplant Eprenetapopt and Azacitidine Maintenance in TP53-Mutant AML and MDS
10/05/2022
True or False: In a recent phase 2 trial, post-transplant eprenetapopt and azacitidine maintenance demonstrated promising safety and efficacy in TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
True or False: In a recent phase 2 trial, post-transplant eprenetapopt and azacitidine maintenance demonstrated promising safety and efficacy in TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
True or False: In a recent phase...
10/05/2022
Oncology
Quiz
Berzosertib Plus Topotecan vs Topotecan Monotherapy for SCLC
01/27/2026
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent...
01/27/2026
Oncology
Quiz
Atezolizumab Plus FOLFIRINOX and Bevacizumab for dMMR/MSI-H mCRC
01/27/2026
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination...
01/27/2026
Oncology
Quiz
Exploring CSF-1-Targeted Therapies for TGCT
01/26/2026
True or false: Investigational agents such as pimicotinib and emactuzumab have shown encouraging activity in tenosynovial giant cell tumor (TGCT), with early data suggesting potentially higher response rates and improved safety profiles.
True or false: Investigational agents such as pimicotinib and emactuzumab have shown encouraging activity in tenosynovial giant cell tumor (TGCT), with early data suggesting potentially higher response rates and improved safety profiles.
True or false: Investigational...
01/26/2026
Oncology
Quiz
Evaluating Targeted Therapies in Glioblastoma
01/26/2026
True or false: Targeted therapies—including immune checkpoint inhibitors (ICIs) and mammalian target of rapamycin (mTOR) inhibitors—did not demonstrate improved survival in unselected glioblastoma populations, according to a systematic review...
True or false: Targeted therapies—including immune checkpoint inhibitors (ICIs) and mammalian target of rapamycin (mTOR) inhibitors—did not demonstrate improved survival in unselected glioblastoma populations, according to a systematic review...
True or false: Targeted...
01/26/2026
Oncology
Quiz
Rovadicitinib for Ruxolitinib-Resistant or Intolerant Myelofibrosis
01/14/2026
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The...
01/14/2026
Oncology
Quiz
CMS4 and Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/13/2026
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus...
01/13/2026
Oncology
Quiz
Eflornithine Plus Lomustine for Recurrent Grade 3 Astrocytoma
01/13/2026
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Eflornithine...
01/13/2026
Oncology
Quiz
Chidamide Plus Azacitidine Maintenance Therapy for AML
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
Quiz
Treatment of Recurrent Refractory Pediatric Low-Grade Glioma (pLGG): Pre-Content Quiz
01/02/2026
01/02/2026
Oncology
Quiz
Molecular Drivers of Pigmented Villonodular Synovitis
12/18/2025
Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?
Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?
Which of the following molecular...
12/18/2025
Oncology

Recent News

FDA Approval
FDA Approves Treosulfan With Fludarabine for Patients With AML or MDS Prior to AlloHSCT
02/07/2025
Emily Estrada
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA...
02/07/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
News
Luspatercept as Novel Standard of Care for ESA-Naive Patients With Transfusion-Dependent, Lower-Risk MDS
10/02/2024
Amber Denham
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new...
10/02/2024
Oncology
News
Initial Low Dose Lenalidomide Over 2 Years Improves Treatment Response Among Non-Transfusion-Dependent Patients With Low-Risk MDS
09/19/2024
Amber Denham
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low...
09/19/2024
Oncology
News
FDA Grants Approval to Imetelstat for Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome With Transfusion-Dependent Anemia
06/21/2024
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to...
06/21/2024
Oncology
News
Azacitidine Maintenance Demonstrates Lower Disease Progression Rate Among Patients With High-Risk FLT3-Negative AML/MDS
03/05/2024

Amber Denham

Amber Denham
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective...
03/05/2024
Oncology
News
Oral Decitabine Cedazuridine Safe, Effective Alternative to Intravenous Decitabine for Patients With MDS or CML
02/21/2024
Amber Denham
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine...
02/21/2024
Oncology
News
Assessment of Individualized MRD With NGS, ddPCR Effective for Early Detection of MDS Relapse
02/09/2024
Amber Denham
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized...
02/09/2024
Oncology
News
Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes
01/31/2024
Amber Denham
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low...
01/31/2024
Oncology
News
Sabatolimab Plus Hypomethylating Agents as Frontline Therapy for Patients With Higher-Risk MDS
01/11/2024
Amber Denham
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that...
01/11/2024
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use